Sandbox endocarditis: Difference between revisions
(2 intermediate revisions by the same user not shown) | |||
Line 204: | Line 204: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Penicillin | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Penicillin Relatively or Fully Resistant Strain (MIC >0.12 >μg/mL)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 237: | Line 237: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 263: | Line 263: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci(MIC > 0.5 µg/ml, consider Enterococcal regimen}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci(MIC > 0.5 µg/ml, consider Enterococcal regimen)}} | ||
|- | |- | ||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | !style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | ||
Line 342: | Line 342: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin}} | ||
|- | |- | ||
Line 371: | Line 371: | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks''''' | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks''''' | ||
|- | |- | ||
|*Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months. | | | ||
*Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months. | |||
*6-wk therapy recommended for patients with symptoms >3 months. | *6-wk therapy recommended for patients with symptoms >3 months. | ||
*Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended. | *Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended. | ||
Line 382: | Line 383: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin}} | ||
|- | |- | ||
Line 425: | Line 426: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|β-Lactamase–producing strain}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|β-Lactamase–producing strain}} | ||
|- | |- | ||
Line 462: | Line 463: | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|E faecium}} | ! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|E faecium}} | ||
|- | |- |
Latest revision as of 21:12, 5 March 2014
Streptococci
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus Bovis Highly Penicillin-Susceptible ▸ Viridans Group Streptococci and Streptococcus Bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL) Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin-Susceptible Strain (MIC ≤ 0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin Relatively or Fully Resistant Strain (MIC >0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml) ▸ Relatively Penicillin-Resistant Streptococci (MIC > 0.5 µg/ml) ▸ Unable to tolerate Penicillin or Ceftriaxone |
|
|
|
|
|
|
|
Enterococci
Endocarditis Caused by Enterococci ▸ Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin ▸ Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin ▸ Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin ▸ Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin |
|
|
|
|
Staphylococci
Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material ▸ Staphylococci (Methicillin Susceptible) ▸ Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci ▸ Oxacillin-Susceptible Strains ▸ Oxacillin-Resistant Strains |
|
|
|
|
HACEK Organisms
HACEK organisms are more indolent and the infection is less complicated. [1]
▸ Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms |
|
- ↑ Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter
|month=
ignored (help)